113 related articles for article (PubMed ID: 15619900)
1. [Quantitative detection of serum hepatitis B wild type virus and the precore mutant genomes using competitive polymerase chain reaction in patients with HBeAg(-) chronic hepatitis B].
Zhang X; Xiong S; Lu Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):33-6. PubMed ID: 15619900
[TBL] [Abstract][Full Text] [Related]
2. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.
Maruyama T; Kuwata S; Koike K; Iino S; Yasuda K; Yotsuyanagi H; Moriya K; Maekawa H; Yamada H; Shibata Y; Milich DR
Hepatology; 1998 Jan; 27(1):245-53. PubMed ID: 9425944
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
[TBL] [Abstract][Full Text] [Related]
4. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
Moutinho RS; Perez RM; Medina-Pestana JO; Figueiredo MS; Koide S; Alberto FL; Silva AE; Ferraz ML
J Med Virol; 2006 Oct; 78(10):1284-8. PubMed ID: 16927290
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
Yoo BC; Kim HJ; Do JH; Park SM
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
7. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
8. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
Akhan SC; Yulugkural Z; Vahaboglu H
Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
[TBL] [Abstract][Full Text] [Related]
9. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
10. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
11. A novel accurate amplification created restriction site method for determination of the wild type and the precore mutant hepatitis B virus variants.
Amini-Bavil-Olyaee S; Sarrami-Forooshani R; Adeli A; Mahboudi F; Sabahi F; Nafisi H; Zali MR; Azizi M
J Virol Methods; 2005 Jul; 127(1):19-23. PubMed ID: 15893561
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.
Rodriguez-Frias F; Jardi R; Buti M; Schaper M; Hermosilla E; Valdes A; Allende H; Martell M; Esteban R; Guardia J
J Viral Hepat; 2006 May; 13(5):343-50. PubMed ID: 16637866
[TBL] [Abstract][Full Text] [Related]
13. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
14. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection.
Bozdayi G; Türkyilmaz AR; Idilman R; Karatayli E; Rota S; Yurdaydin C; Bozdayi AM
J Med Virol; 2005 Aug; 76(4):476-81. PubMed ID: 15977237
[TBL] [Abstract][Full Text] [Related]
15. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
16. Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy.
Yeh CT; Lin WP; Hsu CW; Chang ML; Lin SM; Sheen IS
J Med Virol; 2006 Jul; 78(7):906-10. PubMed ID: 16721857
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
18. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
Hou J; Schilling R; Janssen HL; Hansen BE; Heijtink R; Sablon E; Williams R; Lau GK; Schalm SW; Naoumov NV
J Med Virol; 2007 Aug; 79(8):1055-63. PubMed ID: 17596838
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
20. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
